The established immunotherapies that target surface receptors such as CTLA-4 and/or PD-1 with recombinant antibodies have been crucial for cancer treatment, but a significant population of patients fail to respond to these immunotherapies and a low number of them are finally cured [57]. This evidence concerns the gene CTLA4 and cancer.